Therapeutic | Ruplizumab |
Target | CD40LG |
Heavy Chain | QVQLVQSGAEVVKPGASVKLSCKASGYIFTSYYMYWVKQAPGQGLEWIGEINPSNGDTNFNEKFKSKATLTVDKSASTAYMELSSLRSEDTAVYYCTRSDGRNDMDSWGQGTLVTVSS |
Light Chain | DIVLTQSPATLSVSPGERATISCRASQRVSSSTYSYMHWYQQKPGQPPKLLIKYASNLESGVPARFSGSGSGTDFTLTISSVEPEDFATYYCQHSWEIPPTFGGGTKLEIK |
100% seqID Fv Structure | 1i9r [Fvs: HL, KM, XY] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 1i9r [Fvs: HL, KM, XY] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-II |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | na |
INN Year Proposed | 2000 |
INN Year Recommended | 2001 |
Companies Involved | Biogen |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Autoimmune disorders, Haemophilia A, Idiopathic thrombocytopenic purpura, Multiple sclerosis, Renal transplant rejection, Systemic lupus erythematosus |
Notes |